myNEO announces that promising Covid-19 peptides have been identified which will undergo further preclinical testing. By making smart use of existing cancer treatment technology, the Covid-19 vaccine aims to provide long-term protection to more than 80% of the global population. The vaccine will fight all current Covid-19 forms and other viruses from the corona group such as SARS and MERS.
Now myNEO has found these promising Covid-19 peptides, the company starts pre-clinical trials in collaboration with a European biotech company with a cancer vaccine technology. The goal is to test the vaccine in early 2021 on humans.